MedTrace Logo

Clinical Performance of a Phakic Intraocular Lens (IOL)

NCT03499821 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2026-03-16

Study results available
· View outcomes & findings →

Summary

This study will evaluate the clinical performance of a phakic intraocular lens (IOL) for the improvement of Uncorrected Near Visual Acuity (UCNVA) in subjects who require between +1.00 and +2.50 Reading Add.

Conditions

Interventions

DEVICE

EDOF ICL

The Visian ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens. It offers an intraocular alternative for the correction of refractive error in those who currently utilize spectacle and/or contact lenses correction.

Sponsors & Collaborators

  • Staar Surgical Company

    lead INDUSTRY

Principal Investigators

  • Joanne Egamino, PhD · Staar Surgical Company

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-20
Primary Completion
2019-07-09
Completion
2019-07-09
FDA Device
Yes

Countries

  • Belgium
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03499821 on ClinicalTrials.gov